Page 260 - medicina-integrativa_compress

254 PARTE II, SECCIÓN 3 ENFERMEDADES INFECCIOSAS

chronic hepatitis C treated with interferon-alpha with and without 66. Feher J, Deak G, Muzes G, et al: Hepatoprotective activity of
supplementation with N-acetylcysteine. J Hepatol 28:751-755, 1998. silymarin (Legalon) therapy in patients with chronic liver disease.
42. Anneren G, Magnusson CG, Nordvall SL: Increase in serum Orv Hetil 130:2723-2727, 1989.
concentrations of IgG 2 and IgG 4 by selenium supplementation in 67. Ferenci P, Dragosic SB, Dittrich H: Randomized controlled trial of
children with Down’s syndrome. Arch Dis Child 65:1353-1355, silymarin treatment in patients with cirrhosis of the liver. J Hepatol
1990. 9:105-113, 1989.
43. Jain SK, Pemberton PW, Smith A, et al: Oxidative stress in 68. Pares A, Planas R, Torres M, et al: Effects of silymarin in alcoholic
chronic hepatitis C: Not just a feature of late-stage disease. patients with cirrhosis of the liver: Results of a controlled, double-
J Hepatol 36:805-811, 2002. blinded, randomized and multi-center trial. J Hepatol 28:615-621,
44. Yu MW, Horng IS, Hsu KH, et al: Plasma selenium levels and risk 1998.
for hepatocellular carcinoma among men with chronic hepatitis 69. Tanamly MD, Tadros F, Labeeb S, et al: Randomised double-blinded
virus infection. Am J Epidemiol 150:367-374, 1999. trial evaluating silymarin for chronic hepatitis C in an Egyptian
45. Yu SY, Zhu YJ, Li WG: Protective role of selenium against village: Study description and 12-month results. Dig Liver Dis
hepatitis B virus and primary liver cancer in Qidong. Biol Trace 36:752-759, 2004.
Elem Res 56:117-124, 1997. 70. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C: Milk thistle for
46. Mato JM, Camara J, Fernandez de Paz J, et al: S-Adenosylmethionine alcoholic and/or hepatitis B or C virus liver diseases. Cochrane
in alcoholic liver cirrhosis: A randomized, placebo-controlled, double- Database Syst Rev (2)CD003620, 2005.
blind, multicenter clinical trial. J Hepatol 30:1081-1089, 1999. 71. Dhiman RK, Chawla YK: Herbal medicines for liver diseases.
47. Ansorena E, Garcia-Trevijano E, Martinez-Chantar M, et al: Dig Dis Sci 50:1807-1812, 2005.
S-adenosylmethionine and methylthioadenosine are antiapoptotic 72. Arase Y, Ikeda K, Murashima N, et al: The long-term efficacy of
in cultured rat hepatocytes but proapoptotic in human hepatoma glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494-1500,
cells. Hepatology 35:274-280, 2002. 1997.
48. Podymova SD, Nadinskaia MI: Clinical trial of heptral in patients 73. Liu J, Manheimer E, Tsutani K, Gluud C: Medicinal herbs for
with chronic diffuse liver disease with intrahepatic cholestasis hepatitis C virus infection: A Cochrane hepatobiliary systematic
syndrome. Klin Med (Mosk) 76:45-48, 1998. review of randomized trials. Am J Gastroenterol 98:538-544,
49. Gorbakov VV, Galik VP, Kirillov SM: Experience in heptral 2003.
treatment of diffuse liver diseases. Ter Arkh 70:82-86, 1998. 74. Shiota G, Yamada S, Kawasaki H: Rapid induction of hepatocyte
50. Papakostas GI, Alpert JE, Fava M: S-Adenosyl-methionine in growth factor mRNA after administration of gomisin A, a lignan
depression: A comprehensive review of the literature. component of Shizandra fruits. Res Commun Mol Pathol Pharmacol
Curr Psychiatry Rep 5:460-466, 2003. 94:141-146, 1996.
51. Hagen TM, Ingersoll RT, Lykkesfeldt J, et al: R-alpha-lipoic 75. Ohkura Y, Mizoguchi Y, Morisawa S, et al: Effect of gomisin A
acid-supplemented old rats have improved mitochondrial function, (TJN-101) on the arachidonic acid cascade in macrophages. Jpn J
decreased oxidative damage, and increased metabolic rate. Pharmacol 52:331-336, 1990.
FASEB J 13:411-418, 1999. 76. Ohtaki Y, Hida T, Hiramatsu K, et al: Deoxycholic acid as an
52. Lykkesfeldt J, Hagen TM, Vinarsky V, Ames BN: Age-associated endogenous risk factor for hepatocarcinogenesis and effects of
decline in ascorbic and concentration, recycling and biosynthesis in gomisin A, a lignan component of Schizandra fruits. Anticancer
rat hepatocytes-reversal with R-alpha-lipoic acid supplementation. Res 16:751-755, 1996.
FASEB J 12:1183-1189, 1998. 77. Nomura M, Nakachiyama M, Hida T, et al: Gomisin A, a lignan
53. Bustamante J, Lodge JK, Marcocci L, et al: Alpha-lipoic acid in liver component of Schizandora fruits, inhibits development of
metabolism and disease. Free Rad Biol Med 24:1023-1039, 1998. preneoplastic lesions in rat liver by 3-methyl-4-dimethylamino-
54. Curi R, Lagranha CJ, Doi SQ, et al: Glutamine-dependent changes azobenzene. Cancer Lett 76:11-18, 1994.
in gene expression and protein activity. Cell Biochem Funct 78. Zhu M, Yeung RY, Lin KF, et al: Improvement of phase I drug
23:77-84, 2005. metabolism with Schisandra chinensis against CCl4 hepatotoxicity
55. Rohde T, MacLean DA, Klarlund Pedersen B: Glutamine, in a rat model. Planta Med 66:521-525, 2000.
lymphocyte proliferation and cytokine production. Scand J 79. Iwata H, Tezuka Y, Kadota S, et al: Identification and
Immunol 44:648-650, 1996. characterization of potent CYP3A4 inhibitors in Schisandra fruit
56. Geier A, Reugels M, Weiskirchen R, et al: Common heterozygous extract. Drug Metab Dispos 32:1351-1358, 2004.
hemochromatosis gene mutations are risk factors for inflammation 80. Yoshida Y, Wang MQ, Liu JN, et al: Immunomodulating activity
and fibrosis in chronic hepatitis C. Liver Int 24:285-294, 2004. of Chinese medicinal herbs and Oldenlandia diffusa in particular.
57. Rigamonti C, Andorno S, Maduli E, et al: Gender and liver fibrosis Int J Immunopharmacol 19:359-370, 1997.
in chronic hepatitis: The role of iron status. Aliment Pharmacol 81. Zhang YD, Shen JP, Zhu SH, et al: Effects of astragalus (ASI, SK)
Ther 21:1445-1451, 2005. on experimental liver injury. Yao Xue Xue Bao 27:401-406, 1992.
58. Fontanan RJ, Israel J, LeClair P, et al: Iron reduction before and 82. Zhou X, Dai LL, Jia LP, et al: [Study on the inhibitive effect of
during interferon therapy of chronic hepatitis C: Results of a Astragalus Injection solution on hepatic fibrosis in rats.] Zhonghua
multicenter, randomized, controlled trial. Hepatology 31:730-736, Gan Zang Bing Za Zhi 13:575-578, 2005.
2000. 83. Chen H, Weng L: [Comparison on efficacy in treating liver fibrosis
59. Wallace AE, Weeks WB: Thiamine treatment of chronic hepatitis B of chronic hepatitis B between Astragalus Polygonum anti-fibrosis
infection. Am J Gastroenterol 96:864-868, 2001. decoction and jinshuibao capsule]. Zhongguo Zhong Xi Yi Jie He Za
60. Bosisio E, Benelli C, Pirola O: Effect of the flavanolignans of Zhi 20:255-257, 2000.
Silybum marianum L. on lipid peroxidation in rat liver microsomes 84. Fukudo S, Suzuki J, Tanaka Y, et al: Impact of stress on alcoholic
and freshly isolated hepatocytes. Pharmacol Res 25:147-154, 1992. liver injury: A histopathological study. J Psychosom Res 33:515-521,
61. Saller R, Meier R, Brignoli R: The use of silymarin in the treatment 1989.
of liver diseases. Drugs 61:2035-2063, 2001. 85. Swain MG: Stress and hepatic inflammation. Am J Physiol
62. Valenzuela A, Aspillaga M, Vial S, Guerra R: Selectivity of silymarin 279:G1135-G1138, 2000.
on the increase of the glutathione content in different tissues of the 86. Stausbaugh HJ, Dallman MF, Levine JK: Repeated, but not acute,
rat. Planta Med 55:420-422, 1989. stress suppresses inflammatory plasma extravasation. Proc Natl
63. Soto C, Recoba R, Barron H, et al: Silymarin increases antioxidant Acad Sci 96:14629-14634, 1999.
enzymes in alloxan-induced diabetes in rat pancreas. Comp 87. Regev A, Jeffers LJ: Hepatitis C and alcohol. Alcohol Clin Exp Res
Biochem Physiol C Toxicol Pharmacol 136:205-212, 2003. 23:1543-1551, 1999.
64. Boigk G, Stroeder L, Herbst H, et al: Silymarin retards collagen 88. Mori M, Hara M, Wada I, et al: Prospective study of hepatitis B and
accumulation in early and advanced biliary fibrosis secondary to C viral infections, cigarette smoking, alcohol consumption, and
complete bile duct obliteration in rats. Hepatology 26:643-649, other factors associated with hepatocellular carcinoma risk in Japan.
1997. Am J Epidemiol 151:131-139, 2000.
65. Lieber CS, Leo MA, Qi C, et al: Silymarin retards the progression of 89. El-Zayadi A, Selim O, Hamdy H, et al: Impact of cigarette smoking
alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol on response to interferon therapy in chronic hepatitis C Egyptian
37:336-339, 2003. patients. World J Gastroenterol 10:2963-2966, 2004.